Abstract The taste receptor type 1 (TAS1R) family of heterotrimeric G protein-coupled receptors participates in monitoring energy and nutrient status. TAS1R member 3 (TAS1R3) is a bi-functional protein that recognizes amino acids such as L-glycine and L-glutamate or sweet molecules such as sucrose and fructose when dimerized with TAS1R member 1 (TAS1R1) or TAS1R member 2 (TAS1R2), respectively. It was recently reported that deletion of TAS1R3 expression in Tas1R3 mutant mice leads to increased cortical bone mass but the underlying cellular mechanism leading to this phenotype remains unclear. Here, we independently corroborate the increased thickness of cortical bone in femurs of 20-week-old male Tas1R3 mutant mice and confirm that Tas1R3 is expressed in the bone environment. Tas1R3 is expressed in undifferentiated bone marrow stromal cells (BMSCs) in vitro and its expression is maintained during BMP2-induced osteogenic differentiation. However, levels of the bone formation marker procollagen type I N-terminal propeptide (PINP) are unchanged in the serum of 20-week-old Tas1R3 mutant mice as compared to controls. In contrast, levels of the bone resorption marker collagen type I Ctelopeptide are reduced greater than 60% in Tas1R3 mutant mice. Consistent with this, Tas1R3 and its putative signaling partner Tas1R2 are expressed in primary osteoclasts and their expression levels positively correlate with differentiation status. Collectively, these findings suggest that high bone mass in Tas1R3 mutant mice is due to uncoupled bone remodeling with reduced osteoclast function and provide rationale for future experiments examining the cell-type-dependent role for TAS1R family members in nutrient sensing in postnatal bone remodeling.
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Background
Osteoporosis is a disease of low bone mineral density that is both a significant health problem and a considerable socioeconomic burden, accounting for 1.5 million fractures annually in the USA [2, 18] . Osteoporosis is characterized by an imbalance in bone remodeling in which bone resorption by osteoclasts outpaces bone formation by osteoblasts. Current treatments for osteoporosis have significant limitations [1, 3, 7, 18] , and a better understanding of the endogenous mechanisms regulating bone remodeling is necessary for developing novel treatment strategies. Recent evidence implicates the taste receptor type 1 (TAS1R) family as a novel mechanism regulating postnatal bone homeostasis [16] .
The TAS1R family members TAS1R1, TAS1R2, and TAS1R3 act as nutrient sensors to monitor energy and nutrient status and are expressed in numerous oral and extra-oral tissues including the gastrointestinal tract, brain, bladder, pancreas, male reproductive organs, immune system, adipose tissue, and bone [11] . TAS1R3 is a bi-functional, class C heterotrimeric G protein-coupled receptor that recognizes amino acids such as L-glycine and L-glutamate when dimerized with TAS1R1 or sweet molecules such as sucrose and fructose when dimerized with TAS1R2. Regardless of the ligand, these two responses share a common signaling pathway involving α-gustducin-mediated activation of phospholipase C-β2 (PLCβ2) [11] .
Recently, Simon et al. reported that deletion of the gene encoding TAS1R3 in Tas1R3 mutant mice leads to increased cortical bone mass [16] ; however, the underlying cellular mechanism leading to this phenotype was not examined. Here, we corroborate the finding of high bone mass in Tas1R3 mutant mice and report that levels of the bone resorption marker collagen type I C-telopeptide are reduced greater than 60% in these mice while bone formation markers are unchanged. Consistent with this, Tas1R3 and its putative partner Tas1R2 are expressed in primary osteoclasts and their expression levels positively correlate with differentiation status. Collectively, these findings suggest that high bone mass in Tas1R3 mutant mice is due to uncoupled bone remodeling with reduced osteoclast function and provide rationale for future experiments examining the cell type-dependent role for TAS1R family members in nutrient sensing in postnatal bone remodeling.
Materials and methods

Animals
Tas1R3 mutant mice were described previously [19] . Wildtype C57Bl/6 mice were purchased from Charles River Labs. Animals were given humane care with compliance to institutional guidelines and were allowed ad libitum access to standard chow and tap water under temperature-controlled conditions. Euthanasia was accomplished via exposure to CO 2 followed by cervical dislocation.
Micro-computed tomography (μCT) and histomorphometric analyses
For μCT analyses, bones were collected immediately after sacrifice and fixed in 10% neutral buffered formalin (Millipore, Billerica, MA, USA). Bones were exchanged to 70% ethanol, stored at 4°C, and analyzed at the Harvard School of Dental Medicine μCT Core Facility on a SCANCO μCT 35 scanner. Bone volume and mineral density were determined using the following settings: FOV/Diameter, 7168 μm; voxel size, 7.0 μm; slice increment, 7.0 μm; projections, 500; sample time, 600 ms; μ-scaling, 4096; energy, 55,000 V; intensity, 145 μA. The reader is directed to an excellent guide to μCT in rodents [4] . Femora were subsequently embedded in methyl methacrylate without decalcification, stained using hematoxylin and eosin, von Kossa/ McNeal, or for TRAP activity counterstained with hematoxylin as previously described [15] ; quantification for standard histomorphometric parameters (n = 3 per genotype) by a blinded scorer using morphometric software (OsteoMetrics, Atlanta, GA, USA). The reader is directed to an excellent guide to bone histomorphometry [5] .
Cell culture
MC3T3-E1 and MLO-Y4 cells were obtained from ATCC. Bone marrow stromal cells (BMSCs) were isolated from the long bones of male C57Bl/6 mice (Charles River Labs, Wilmington, MA, USA) between 10 and 13 weeks of age as previously described [9] . Cells were maintained in DMEM (MC3T3-E1 and MLO-Y4 cells) or α-MEM (BMSCs) supplemented with 10% FBS (Thermo-Fisher Scientific, Waltham, MA, USA). BMSC differentiation was accomplished by treatment with 100 ng/ml BMP2 (R&D Systems, Minneapolis, MN, USA) for 7 days; RNA was isolated on day 0 and day 7 for subsequent RT-PCR analyses.
Primary bone marrow macrophages (BMMs) were flushed from femurs and tibiae of C57Bl/6 mice. Red blood cells were lysed with RBC lysis buffer (150 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA, pH 7.4). BMMs were spun down, resuspended in minimal essential media α (Thermo-Fisher Scientific) supplemented with 1% CMG 14-12 cultured supernatant containing M-CSF, and plated on 100-mm tissue culture plates overnight. The following day, the nonadherent population of cells was counted and plated for experiments. Cells were maintained in medium containing M-CSF for two more days, at which time media was replaced with medium containing 1% CMG 14-12 culture supernatant and 30 ng/mL RANKL (R&D Systems) to initiate osteoclast differentiation for up to 3 days before harvesting.
Gene expression analyses
For gene expression studies, total RNA was isolated from isolated cells or marrow-free humerii as previously described [13] . Reverse transcription was performed using the SuperScript III First-Strand Synthesis SuperMix (ThermoFisher Scientific); cDNA from primary murine osteoclasts was generated as described previously [15] . PCR was carried out with GoTaq (Promega, Madison, WI, USA) or OneTaq (New England Biolabs, Ipswich, MA, USA) and the following primer pairs: Tas1R1, 5′-CTGCCAAAGGACAG AATCCTC-3′ and 5′-GAACCGCATGGCTTGGAAG-3′; Tas1R2, 5′-AGCGTGTGGTCTACAGTGTG-3′ and 5′-TCTCCCTGAGTAGCTGCCAT-3′; Tas1R3, 5′-TGGG GGCCTCTTTGTGTCT-3′ and 5′-TGGGTTGTGTTCTC TGGTTGA-3′; Ctsk, 5′-AGCGAACAGATTCTCAACAG C-3′ and 5′-AGACAGAGCAAAGCTCACCAT-3′; Osterix/ Sp, 5′-AGAGATCTGAGCTGGGTAGAGG-3′ and 5′-AAGAGAGCCTGGCAAGAGG-3′; Rankl/Tnfsf11, 5′-A G C C AT T T G C A C A C C T C A C -3 ′ a n d 5 ′ -C G T G GTACCAAGAGGACAGAGT-3′; Trap/Acp5, 5′-CGTC TCTGCACAGATTGCAT-3′ and 5′-AAGCGCAAACGGTA GTAAGG-3′; Hprt, 5′-CCTGCTGGATTACATTAAAG CACTG-3′ and 5′-GTCAAGGGCATATCCAACAA CAAAC-3′. Negative controls for PCR targets were accomplished using reaction lacking template DNA.
For quantitative real-time PCR experiments, RNA was harvested from BMSCs or osteoclasts using TRIzol Reagent (Thermo-Fisher Scientific) or RNEasy Kit (QIAGEN, Hilden, Germany). cDNA was prepared using the iScript cDNA Synthesis Kit (Biorad, Hercules, CA, USA). Reactions were run using LightCycler 480 SYBR Green I Master (Roche, Basel, Switzerland) on the Roche LightCycler 480 using the primer pairs listed above.
Serum immunoassays
Serum samples were obtained as previously described [17] , and levels of PINP, CTx, and TRAP were measured using the Mouse PINP ELISA Kit, Mouse CTX-1 ELISA Kit, and Mouse TRAP ELISA Kit by NeoScientific (Cambridge, MA, USA), respectively, according to the manufacturer's instructions.
Statistical considerations
Data were plotted in GraphPad Prism 6 and statistical tests completed as detailed in the figure or table legends; p < 0.05 was considered significant.
Results
Increased cortical bone in Tas1R3 mutant mice
We first sought to corroborate the report of increased cortical bone mass in the femora of Tas1R3 mutant mice. Similar to the report by Simon et al. [15] , μCT analyses performed on a small cohort of 20-week-old male mice revealed a modest increase (+ 13%) in average thickness of the cortical bone at the femoral mid-diaphysis of Tas1R3 mutant mice as compared to wild-type littermates (Fig. 1a-b) . And, consistent with our previous results [9] , RT-PCR analysis on RNA from marrow-free humeral diaphyses of 9-week-old wild-type mice confirmed that Tas1R3 is expressed in the postnatal bone micro-environment along with its putative signaling partners Tas1R1 and Tas1R2 (Fig. 1c) .
TAS1R3 in bone formation
We next sought to determine if osteoblast lineage cells express TAS1R3. These experiments revealed that Tas1R3 transcript is present in undifferentiated primary murine bone marrow stromal cells (BMSCs) (Fig. 2a) and its expression level is maintained during BMP2-induced differentiation of these cells (Fig. 2b) ; increased expression of the osteoblast lineage marker Osterix/Sp7 (Fig. 2c) serves as a positive control for differentiation in this assay. Consistent with this result, Tas1R3 transcript is present in the osteoblastic cell line MC3T3-E1 and the osteocyte-like cell line MLO-Y4 (Fig.  2d) ; no attempt was made to quantitatively compare expression levels of Tas1R3 between these cell lines or against primary BMSCs.
These findings raised the possibility that loss of TAS1R3 function in the osteoprogenitor lineage might underlie high bone mass in Tas1R3 mutant mice. To test this idea, we examined osteoblast parameters by static histomorphometry and osteoblast function by quantifying serum levels of the bone formation marker procollagen type I N-terminal propeptide (PINP). No differences were observed between control and Tas1R3 mutant mice in these analyses (Table 1 and Fig. 2e) suggesting that, although cells of the bone-forming lineage express TAS1R3, its absence does not lead to altered osteoblast differentiation or activity.
TAS1R3 in bone resorption
We next examined a possible role for TAS1R3 in bone resorption and found that serum levels of the bone resorption marker collagen type I C-telopeptide (CTx) are reduced by greater than 60% in Tas1R3 mutant mice (Fig. 3a) . Consistent with this idea, Tas1R3 is expressed in primary murine osteoclasts in vitro along with its putative signaling partner Tas1R2 (Fig.  3b) ; Tas1R1 expression was not observed in these cells (data not shown). Additionally, increased expression of Tas1R3 and Tas1R2 correlates with the robust increase in expression of the mature osteoclast marker Cathepsin K (Ctsk) observed during the differentiation period (Fig. 3c-e) . These data raised the possibility that defective osteoclast differentiation may underlie the reduction in bone resorption observed in Tas1R3 mutant mice. However, static histomorphometric analyses indicate that osteoclast number is unchanged in the absence of TAS1R3 (Table 1) , which is supported by the fact that skeletal expression levels of Rankl/Tnfsf11 (Fig. 3f) and Trap/Acp5 (Fig. 3g) and serum levels of TRAP (Fig. 3h) are comparable between control and Tas1R3 mutant mice. Collectively, our findings suggest that global absence of TAS1R3 function leads to uncoupled bone remodeling due to reduced osteoclast activity.
Discussion
Our study corroborates the finding of elevated cortical bone mass in Tas1R3 mutant mice recently reported by Simon et al. [16] and addresses the open question regarding the cellular mechanism(s) underlying high bone mass in mice. Although Tas1R3 expression has been previously observed in the skeleton [10] , we are the first to detail the specific skeletal cell types that express TAS1R family members in vitro. In particular, Tas1R3 and Tas1R2 are expressed endogenously in murine osteoclast precursors, and their expression levels parallel the robust increase in the osteoclast marker Ctsk during osteoclast differentiation. In contrast, Tas1R1 expression is undetectable in these assays, suggesting TAS1R3 functions in conjunction with TAS1R2 in osteoclasts. This idea is consistent with the fact that, similar to Tas1R3 mutant mice, global loss of Tas1R2 also leads to high bone mass through an undetermined mechanism [16] .
The specific role that TAS1R2 and TAS1R3 play in osteoclast cells remains unknown. However, a requirement for TAS1R3 function in bone resorption in vivo is confirmed by the fact that Tas1R3 mutant mice display a profound reduction in serum levels of the bone resorption marker CTx in comparison to wild-type mice. In contrast, TAS1R family members are expressed in the osteoblast lineage in vitro, yet serum levels of the bone formation marker PINP is unchanged in Tas1R3 mutant mice. While we are unable to comment on the specific molecule(s) mediating activation of TAS1R2 and TAS1R3 in the osteoclast lineage in vivo, glucose is one compelling possibility among the host of putative ligands [14] . For example, reducing glucose availability impairs osteoclast activity in vitro [8] , and glycolytic inhibitors reduce bone resorption in vivo [6, 12] . This presents the hypothesis that reduced glucose sensing by osteoclasts in Tas1R3 mutant mice leads to defective bone resorption. Additionally, prior work indicates that loss of TAS1R3 function is associated with decreased mammalian target of rapamycin complex 1 (mTORC1) activity and increased autophagy [17] . We must also acknowledge that the global nature of the Tas1R3 mutation, coupled with the expression of this receptor in numerous extra-skeletal sites [11] , leaves open the possibility that impairment of bone resorption in Tas1R3 mutant mice is secondary to losing TAS1R3 function in another physiological context. Future studies involving cell type-dependent knock-out of Tas1R3 are required to differentiate between these possibilities, but these studies are not yet possible due to the lack of a conditional Tas1R3 allele.
In conclusion, our findings provide novel insight into the role of TAS1R family members in skeletal biology and postnatal bone remodeling. These results and the stated limitations provide rationale for future experiments examining the cell type-dependent role for TAS1R family members in nutrient Fig. 3 TAS1R3 in bone resorption. a Quantification of collagen type I Ctelopeptide (CTx) levels in serum from 20-week-old wild-type male and Tas1R3 knock-out (KO) mice; data are expressed as mean ± SEM. n = 3 for each group. * indicates p < 0.04 by unpaired t test. b RT-PCR for TAS1R family members in differentiated primary murine osteoclasts (OCLs). Hprt serves as loading control. Data are representative of four independent differentiated OCL samples. c-e Quantitative RT-PCR for Tas1R3 (c) and Tas1R2 (d) expression from non-adherent murine bone marrow cells undergoing osteoclast differentiation in vitro. Cathepsin K (Ctsk) serves as positive control for osteoclast differentiation (e). Data are expressed as mean ± SEM fold-change relative to time course day 0 from five independent experiments. * indicates p < 0.02 by ratio paired t test. fg Quantitative RT-PCR for Rankl/Tnfsf11 (f) and Trap/Acp5 (g) using RNA obtained from 20-week-old humerii; data are expressed as mean ± SEM. n = 5 for each group. h Quantification of TRAP levels in serum from 20-week-old male mice; data are expressed as mean ± SEM. n = 8 for each group sensing by osteoclasts and/or osteoblasts in the postnatal skeleton.
